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ABSTRACT
Background: Joint space narrowing ( JSN) in
rheumatoid arthritis (RA) may be a manifestation of
(primary) osteoarthritis becoming more prominent
with age. We investigated the severity and predictors of
JSN progression among different age groups.
Methods: 10-year follow-up data of the BeSt study, a
randomised controlled treat-to-target trial in early RA
were used. Annual X-rays of hands and feet were
scored using the Sharp/van der Heijde score (SHS).
Subgroups were defined by age at baseline: 55,
40<55 and <40 years. JSN progression predictors
were assessed by Poisson regression.
Results: Baseline JSN scores (median (IQR)) were
higher in patients 55 (2.0 (0.0–6.0)) compared with
the other age groups: 1.0 (0.0–3.0) 40<55 and 0.3
(0.0–3.0) <40, p<0.001. After 10 years, total JSN and
SHS were similar in all age groups. In patients 55
the mean erythrocyte sedimentation rate (ESR) over
time (relative risk 1.02 (95% CI 1.00 to 1.03)) and the
combined presence of rheumatoid factor and
anticitrullinated protein antibodies (RF+/ACPA+) (3.27
(1.25–8.53)) were significantly correlated with JSN
progression. In patients <40 the baseline swollen joint
count (SJC; 1.09 (1.01–1.18)) and ESR over time
(1.04 (1.02–1.06)) were significantly associated.
Conclusions: At baseline, patients with RA 55 years
had more JSN than younger patients but after 10 years
JSN scores were similar between age groups.
Independent risk factors for JSN progression were
baseline SJC and ESR over time in patients <40, RF
+/ACPA+ and ESR over time in patients 55 years.
This suggests that mechanisms leading to JSN
progression are related to (residual) rheumatoid
inflammation and vary between age groups. These
mechanisms remain to be elucidated.
Trial registration numbers: NTR262, NTR265.
INTRODUCTION
Joint damage in rheumatoid arthritis (RA)
causes progressive disability in patients.1
Synovial inﬂammation activates an immune
process that causes articular cartilage
degradation leading to joint space narrowing
( JSN) and excessive local bone resorption
and inadequate bone formation resulting in
bone erosions.2 3 Presence and progression
of bone erosions and JSN can be scored
using plain radiographs of hands and feet
using the Sharp/van der Heijde score
(SHS).4 It is well known that joint damage
progression is a result of continued high
disease activity.5 Thus, scoring progression of
radiographic damage may affect how efﬁcacy
of treatment is interpreted, and can inﬂu-
ence therapeutic decisions.
However, progression of JSN, and probably
to a lesser extent of erosions, may also be a
manifestation of primary osteoarthritis (OA)
becoming more prominent with increasing
age. Lawrence et al6 showed age-related
increases in radiographic OA in both women
Key messages
What is already known about this subject?
▸ Joint space narrowing ( JSN) in rheumatoid arth-
ritis may be a manifestation of (primary) osteo-
arthritis becoming more prominent with age.
▸ Older rheumatoid arthritis patients have higher
damage scores in early disease, partly caused
by more JSN.
What does this study add?
▸ JSN scores at baseline are higher in older age
groups, particularly in the proximal interphalan-
geal joints.
▸ After 10 years no statistical difference in JSN
scores between age groups is observed;
however, risk factors for JSN progression differ
between age groups.
How might this impact on clinical practice?
▸ JSN in older patients in early rheumatoid
disease might be a manifestation of primary
osteoarthritis and should be interpreted with
caution.
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(prevalence OA of 7.6% in those aged 15<24 vs 97%
in patients >65) and men (prevalence OA of 9.4% in
those aged 15<24 vs 97% in patients >65). OA progres-
sion seems to be relatively slow but more frequent and
more severe OA progression in the distal and proximal
interphalangeal joints of older patients was reported pre-
viously.7 8 No deﬁnite clinical progression risk factors for
radiographic OA progression are known. More painful
joints and more self-reported pain appear to increase
radiographic OA progression.9
Older patients with RA are shown to have a higher
baseline damage score. Khanna et al10 showed that this
was mainly due to more JSN, and this associated with
features of hand OA. However, Mangnus et al11 showed
that the difference between different age groups could
not be fully explained by JSN. Others reported that
patients with a higher age at onset were more often
anticitrullinated protein antibodies (ACPA) positive and
had more erosions at baseline, and also higher disease
activity scores (DASs) and higher erosion scores during
the ﬁrst 2 years of treatment.12 13 Still others showed
that in advanced RA, older patients had more JSN than
younger patients.14
We hypothesised that JSN progression may show a dif-
ferent pattern in older than in younger patients with RA.
In addition, predictors of JSN may be different between
these age groups, due to primary OA becoming more
prominent with increasing age. We aimed to identify and
compare age-speciﬁc baseline risk factors for the develop-
ment of JSN in patients who participated in the BeSt
study, a multicentre randomised clinical trial. Patients
with early RA were treated according to one of four
dynamic treatment strategies all aiming a low disease
activity (DAS≤2.4). Patients were followed for 10 years
and radiographs of hands and feet were obtained annu-
ally to score the bone erosions and JSN by the SHS.
PATIENTS AND METHODS
Participants and design
The BeSt (Dutch acronym for treatment strategies) a
multicentre, randomised clinical trial included 508
patients with recent-onset active RA (1987 revised
American College of Rheumatology criteria15) and a
symptom duration ≤2 years. All participants gave written
informed consent and the Medical Ethics Committee of
each participating centre approved the study protocol.
Patients were randomised into four treatment strat-
egies: (1) sequential monotherapy; (2) step-up combin-
ation therapy; (3) initial combination therapy with
methotrexate, sulfasalazine and prednisone; and (4)
initial combination therapy with methotrexate and
inﬂiximab. Treatment adjustments were made every
3 months aiming at a DAS<2.4. If DAS was ≤2.4 for
6 months, treatment could be tapered to maintenance
dose, and if then DAS<1.6 was achieved for another
6 months, medication was discontinued. Once the DAS
was 1.6 treatment was restarted. Details of the BeSt
study have been published elsewhere.16 17
Methods of measurement
At baseline, rheumatoid factor (RF) status was evaluated.
ACPA status was determined afterwards by the anticyclic
citrullinated peptide test in available stored baseline
serum samples. Health assessment questionnaires
(HAQs)18 and the DAS were assessed at baseline and
every 3 months for 10 years. Baseline and annual radio-
graphs, up to 10 years, of hands and feet were collected
and were scored, by two independent readers, blinded
for patient identity and time order, using the SHS.4
Statistical analysis
Median age at baseline in our population was
54.9 years. Based on this median, and considering the
unlikelihood of OA in patients <40 years old6 three
arbitrary subgroups were created: ‘group <40’ compris-
ing patients aged <40 years, ‘group 40<55’ with
patients 40 years but <55 years and ‘group 55’ with
patients 55 years old at baseline. Baseline character-
istics were compared with the multinomial variable ‘age
group’ by the χ2 test, one-way analysis of variance and
Mann-Whitney U test. Pairwise comparisons between
the age groups were performed with the χ2 test, t-test
and Kruskall-Wallis test. Mean SHS, erosion and JSN
(progression) scores after 10 years were compared
between groups using one-way analysis of variance, with
robust SE estimation and p values because of the
skewed non-normal distributions.
After 10 years, DAS and HAQ were known for 292/
508 patients, and radiographs were available for 278/508
patients. To avoid bias due to missing data, multiple
imputation techniques were performed. The imputed
values are based on all radiographs in the study, and are
consequently less sensitive to one measurement error or
picture of low quality. To improve resemblance to the
normal distribution, annual JSN and erosion scores were
log-transformed before imputing. The imputation
model incorporated the baseline variables: age, sex,
body mass index (BMI), smoking status, randomisation
arm, RF status, ACPA status, log-transformed erosion and
narrowing score, HAQ score and the components of the
DAS. Annual log-transformed erosion and narrowing
scores, 10-year HAQ scores and biannual DAS were also
included in the imputation model.
SHS and JSN scores are always whole non-negative
numbers and therefore, JSN progression scores are inte-
gers. In our study, only 2.2% of the progression scores
were negative; hence, JSN progression is approximately a
count. Furthermore, 37% of the patients had zero JSN
progression. For regression modelling of the JSN pro-
gression, we used robust Poisson regression after setting
the negative progressions to zero. This regression
method assumes that the covariates have a multiplicative
effect on the mean progression scores, but remains valid
if the Poisson regression is violated. We report the
2 Matthijssen XME, et al. RMD Open 2016;2:e000338. doi:10.1136/rmdopen-2016-000338
RMD Open
group.bmj.com on November 11, 2016 - Published by http://rmdopen.bmj.com/Downloaded from 
exponentiated regression coefﬁcients, which are inter-
preted as ratios of means (relative to the reference cat-
egory for categorical predictors, or corresponding to a
one unit increase for numerical predictors). When ana-
lyses were carried out separately for each age group, we
applied Bonferroni correction to adjust for multiple
testing.
In the multivariate analysis, RF status and ACPA status
were coded into one variable because both antibodies
are frequently present in the same patients and conse-
quently their inﬂuence is confounded by the effect of
the other antibody. Since treatment strategy is randomly
allocated, it does not confound the effect of other vari-
ables and was therefore not included in the multivariate
models. All risk factors with a p value <0.2 were entered
in the multivariate models with Bonferroni correction to
correct for multiple testing. Accordingly, predictor vari-
ables with p values <0.0167 were considered signiﬁcant,
98.33% CIs are given, and only predictor variables with
univariate p values <0.066 were entered in the multivari-
ate model. Since we selected our regression variables
carefully, we did not remove the determinants from the
multivariate analysis when they did not attain signiﬁ-
cance. Analyses were performed with SPSS V.20.0.
RESULTS
Baseline
In the BeSt study, 508 patients were included, 81 (16%)
aged <40, 179 (35%) aged 40<55 and 248 (49%) aged
55. Mean age at baseline was 33, 49 and 66 in the
three age groups, respectively. Table 1 shows the baseline
characteristics of the three age groups.
The variables that were statistically signiﬁcantly asso-
ciated with the multinomial variable ‘age group’ (<40,
40<55 and 55) showed statistically signiﬁcant differ-
ences when compared pairwise between age groups.
Thirty per cent, 44% and 30% of the three age groups
participants were noted as ‘smokers’ at baseline (group
40<55 vs group 55, p=0.004). Mean BMI was 24.4 in
group <40, 26.6 in group 40<55 (group <40 vs group
40<55, p<0.001) and in 26.1 in group 55 (group <40
vs group 55, p=0.001). Erythrocyte sedimentation rate
(ESR) was higher in group 55 compared with group
<40 (mean 46 vs 37; p=0.01) and group 40<55 (mean
46 vs 35; p<0.001). Time from diagnosis was lower in
group <40 compared with group 40<55 and group 55
(p=0.002 and p=0.004, respectively).
Pairwise age group comparison of the variables not
statistically signiﬁcantly associated with ‘age group’ was
Table 1 Baseline characteristics in the different age groups
Group <40 Group 40<55 Group 55
n=81 n=179 n=248 p Value
Age, mean±SD, years 33±6 49±5 66±8
Women, n (%) 61 (75) 125 (70) 157 (63) 0.10
Smoking, no (%) 25 (30) 78 (44) 74 (30) 0.01
BMI, mean±SD 24.4±4.3 26.6±4.5 26.1±3.8 0.001
Time from diagnosis to inclusion, median weeks (IQR) 1.6 (0.7–3.1) 2.4 (1.0–5.3) 2.7 (1.0–4.7) 0.004
Symptom duration, median weeks (IQR) 26.1 (13.4–57.9) 24.6 (15.3–56.1) 22.4 (13.3–44.3) 0.25
RF positive, n (%) 53 (65) 123 (69) 153 (62) 0.32
ACPA positive, n/total n (%) 43/78 (55) 116/169 (69) 132/226 (58) 0.05
DAS, mean±SD 4.4±0.9 4.3±0.8 4.5±0.9 0.12
HAQ score, 0–3 scale, mean±SD 1.3±0.7 1.4±0.6 1.4±0.7 0.49
CRP, mean±SD 35.4±43.2 32.8±41.9 41.1±43.2 0.14
ESR, mean±SD 37.1±25.4 34.7±25.7 45.8±28.4 <0.001
Ritchie Articular Index 14 (9–20) 13 (10–17) 13 (9–18) 0.53
Swollen joint count 14 (10–18) 12 (9–18) 14 (10–19) 0.06
Total SHS (0–448 scale)
Median (IQR) 1.0 (0.0–3.0) 1.0 (0.0–4.5) 2.5 (1.0–7.4) <0.001
Mean±SD 2.4±3.7 3.1±4.9 5.0±6.8
Erosion score, 0–280 scale
Median (IQR) 0.0 (0.0–0.3) 1.0 (0.0–3.0) 0.0 (0.0–1.0) <0.001
Mean±SD 0.5±1.4 0.9±2.6 1.1±2.0
JSN score, 0–168 scale
Median (IQR) 0.3 (0.0–3.0) 1.0 (0.0–3.0) 2.0 (0.0–6.0) <0.001
Mean±SD 1.9±2.9 2.2±3.2 3.9±5.5
Treatment strategy
Sequential monotherapy, n (%) 19 (24) 51 (29) 56 (23) 0.52
Step-up therapy, n (%) 18 (22) 47 (26) 56 (23)
Initial combination therapy with prednisone, n (%) 22 (27) 45 (25) 66 (27)
Initial combination therapy with infliximab, n (%) 22 (27) 36 (20) 70 (28)
ACPA, anticitrullinated protein antibodies; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ,
health assessment questionnaire; JSN, joint space narrowing; RF, rheumatoid factor; SHS, Sharp/van der Heijde score.
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Table 2 Outcomes 10 years after randomisation
Group <40 Group 40<55 Group 55 p Value p Value p Value
n=81 n=179 n=248 <40 vs 40<55 <40 vs 55 40<55 vs 55
DAS over time, mean±SD 2.0±0.7 2.0±0.6 2.1±0.6 0.68 0.57 0.18
ESR over time, mean±SD 17.2±12.3 17.8±11.6 22.1±16.1 0.73 0.01 <0.01
Total SHS, 0–448 scale
Median (IQR) 4.1 (1.2–12.5) 6.5 (2.0–15.5) 7.0 (3.0–15.5) 0.69 0.57 0.75
Mean±SD 15.0±32.4 13.5±20.3 12.9±17.1
SHS progression
Median (IQR) 2.7 (0.0–7.0) 3.0 (0.5–11.7) 2.5 (0.5–8.4) 0.54 0.19 0.15
Mean±SD 12.6±31.0 10.4±18.5 7.8±15.9
Erosion score, 0–280 scale
Median (IQR) 1.0 (0.0–3.8) 1.3 (0.3–5.0) 1.5 (0.5–4.0) 0.91 0.37 0.07
Mean±SD 4.9±13.0 5.1±9.6 3.6±6.5
Erosion progression
Median (IQR) 0.8 (0.0–3.0) 1.0 (0.0–4.0) 0.8 (0.0–2.1) 0.93 0.20 0.02
Mean±SD 4.3±12.7 4.2±8.1 2.5±6.2
JSN score, 0–168 scale
Median (IQR) 3.0 (0.5–8.0) 4.0 (1.0–10.0) 5.3 (2.0–11.5) 0.48 0.73 0.47
Mean±SD 10.1±20.4 8.4±12.4 9.4±12.0
JSN progression
Median (IQR) 1.0 (0.0–5.0) 1.9 (0.0–7.5) 1.8 (0.0–5.5) 0.36 0.20 0.49
Mean±SD 8.2±19.3 6.2±11.6 5.4±11.2
DAS, disease activity score; ESR, erythrocyte sedimentation rate; SHS, Sharp/van der Heijde score; JSN, joint space narrowing.
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performed, but showed no statistically signiﬁcant differ-
ences between groups except for DAS and swollen joint
count (SJC; data not shown). Age group <40 had similar
baseline DAS and SJC compared with groups 40<55
and 55. Group 40<55 had lower DAS compared with
group 55 (4.3 vs 4.5; p=0.04) and a lower baseline SJC
compared with group 55 (median ( IQR): 12 (9–18) vs
14 (10–19); p=0.02). More patients were ACPA positive
in group 40<55 than in group <40 (68% vs 55%;
p=0.05) and group 55 (68% vs 58%; p=0.05). Both
ACPA and RF were present in 46%, 60% and 48% of the
patients in group <40, group 40<55 and group 55,
respectively.
All baseline radiographic scores were similar in group
<40 and group 40<55. Baseline SHS was higher in
group 55 (median 2.5, IQR 1.0–7.4) compared with
the other groups (group <40: 1.0 (0.0–3.0); group
40<55: 1.0 (0.0–4.5); p<0.001). Baseline erosion scores
were higher in group 55 compared with group 40<55
(1.0 (0.0–3.0) vs 0.0 (0.0–1.0); p=0.006) and group <40
(0.0 (0.0–0.3); p<0.001). Also, more patients in group
55 had JSN0.5 (70% vs 50% in group <40; p=0.001;
and 55% in group 40<55; p=0.002) and the median
JSN score was higher compared with the other groups
(2.0 (0.0–6.0) in group 55 vs 0.3 (0.0–3.0) in group
<40 and 1.0 (0.0–3.0) in group 40<55; p<0.001). JSN in
the proximal interphalangeal joints increased with age:
(mean±SD) 0.1±0.5 (median (IQR) 0.0 (0.0–0.0)) in
group <40, 0.2±0.5 (0.0 (0.0–0.0)) in group 40<55 and
0.4±0.9 (0.0 (0.0–0.5)) in group 55 (<40 vs 40<55
p=0.06; <40 vs 55 p=0.001; 40<55 vs 55 p=0.02).
This trend was not observed in the metacarpophalangeal
joints. JSN scores in metacarpophalangeal joints are
higher in group 55 compared with group 40<55 (0.6
±1.2 (0.0 (0.0–1.0)) vs 0.4±0.9 (0.0 (0.0–0.0)), p=0.01)
but not compared with group <40 (0.5±0.9 (0.0 (0.0–
1.0)); <40 vs 55, p=0.51).
Outcomes after 10 years
The 10-year follow-up characteristics are shown in table 2.
Average DAS over time was similar in all groups. ESR over
time was higher in group 55 (mean 22) compared with
the other groups (mean 17 <40 and mean 18 in group
40<55; p=0.01 group <40 vs 55, p<0.01 group 40<55
vs 55). After 10 years of follow-up none of the mean
radiographic scores differed between the age groups but
JSN0.5 was found more often in group 55 (90%) com-
pared with group <40 (75%) and in group 40<55 (80%;
p=0.001 and p=0.008, respectively).
SHS progression was similar in all groups (2.7 (0.0–
7.0); 3.0 (0.5–11.7); 2.5 (0.5–8.4)). Erosion progression
scores were higher in group 40<55 compared with
group 55 (1.0 (0.0–4.0) vs 0.8 (0.0–2.1); p=0.02). JSN
progression did not differ statistically signiﬁcantly
between the age groups: (mean±SD) 8.2±19.3 (median
(IQR) 1.0 (0.0–5.0)) in group <40, 6.2±11.6 (1.9 (0.0–
7.5)) in group 40<55 and 5.4±11.2 (1.8 (0.0–5.5)) in
group 55. Scores at 10 years and progression scores are
Figure 1 Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest
dots: group <40, lightest dots group 40<55, intermediate dots: group 55; uploaded as a separate file). JSN, joint space
narrowing.
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shown in ﬁgure 1. While the median progression scores
are higher in the oldest groups, JSN progression scores
are more skewed to the right (higher progression
scores) in the youngest group, as reﬂected by a higher
mean and higher SD in that group.
Predictive factors for JSN progression
Univariate risk factors that were statistically signiﬁcantly
associated with JSN progression in group <40 were JSN
at baseline (relative risk (IQR); 1.17 (1.01–1.35)), base-
line SJC (1.11 (1.02–1.21)), ACPA+ (3.79 (1.21–11.89)),
RF+/ACPA+ (5.39 (1.25–23.15)) and average ESR over
time (1.04 (1.00–1.08); table 3) and initial combination
therapy with inﬂiximab was protective against JSN pro-
gression compared with sequential monotherapy (0.20
(0.04–0.95)). In group 40<55, erosions at baseline
(1.06 (1.01–1.12)), RF+ (2.88 (1.40–5.96)), RF+/ACPA+
(3.41 (1.33–8.71)) and average ESR (1.02 (1.00–1.04))
were correlated with JSN progression. Also, initial com-
bination therapy with inﬂiximab (0.49 (0.19–1.27)) com-
pared with sequential monotherapy tended to protect
against JSN progression in group 40<55. In group 55,
smoking (2.00 (1.11–3.58)), RF+ (2.63 (1.31–5.28)),
ACPA+ (3.39 (1.58–7.28)), RF+/ACPA+ (4.19 (1.58–
11.07)) and average ESR (1.02 (1.01–1.03)) were statis-
tically signiﬁcantly related to JSN progression. Treatment
strategies were not correlated with JSN progression in
group 55.
Risk factors with a p value <0.067 were entered in the
multivariate analysis per age group (table 4). In the
Table 3 Univariate Poisson regression analysis per age group
Group <40 Group 40<55 Group 55
RR (95% CI) RR (95% CI) RR (95% CI)
Baseline smoking 0.83 (0.16 to 4.23) 1.18 (0.60 to 2.32) 2.00 (1.11 to 3.58)
BMI<25 Ref Ref Ref
BMI>25<30 0.91 (0.22 to 3.82) 0.58 (0.37 to 1.50) 1.12 (0.58 to 2.14)
BMI>30 0.28 (0.05 to 1.66) 0.74 (0.19 to 1.73) 1.19 (0.50 to 2.87)
Ritchie Articular Index 1.00 (0.94 to 1.06) 0.95 (0.89 to 1.01) 0.98 (0.93 to 1.03)
Swollen joint count 1.11 (1.02 to 1.21) 0.97 (0.93 to 1.01) 1.01 (0.98 to 1.05)
JSN 1.17 (1.01 to 1.35) 1.06 (0.99 to 1.14) 1.00 (0.94 to 1.07)
Erosions 1.13 (0.90 to 1.41) 1.06 (1.01 to 1.12) 1.02 (0.89 to 1.15)
RF−/ACPA− Ref Ref Ref
RF+/ACPA− 1.65 (0.28 to 9.82) 3.31 (0.93 to 11.75) 1.47 (0.48 to 4.47)
RF−/ACPA+ 2.78 (0.48 to 16.15) 1.76 (0.54 to 5.79) 2.52 (0.84 to 7.54)
RF+/ACPA+ 5.39 (1.25 to 23.15) 3.41 (1.33 to 8.71) 4.19 (1.58 to 11.07)
RF− Ref Ref Ref
RF+ 2.81 (0.90 to 8.77) 2.88 (1.40 to 5.96) 2.63 (1.31 to 5.28)
ACPA− Ref Ref Ref
ACPA+ 3.79 (1.21 to 11.89) 2.02 (0.94 to 4.33) 3.39 (1.58 to 7.28)
Average ESR over time 1.04 (1.00 to 1.08) 1.02 (1.00 to 1.04) 1.02 (1.01 to 1.03)
Sequential monotherapy Ref Ref Ref
Step up to combination therapy 0.44 (0.07 to 2.79) 1.29 (0.56 to 3.02) 0.81 (0.34 to 1.93)
Initial combination therapy with prednisone 0.89 (0.20 to 3.93) 0.77 (0.36 to 1.64) 0.93 (0.38 to 2.25)
Initial combination therapy with infliximab 0.20 (0.04 to 0.95) 0.49 (0.19 to 1.27) 0.84 (0.36 to 2.00)
Bold typeface represents risk factors that attained significance.
95% CI, 98.33% (Bonferroni correction) CI; ACPA, anticitrullinated protein antibodies; BMI, body mass index; Erosions, erosion score (SHS);
ESR, erythrocyte sedimentation rate; JSN, joint space narrowing; RF, rheumatoid factor; RR, relative risk; SHS, Sharp/van der Heijde score.
Table 4 Multivariate Poisson regression analysis per age
group
Group <40 RR (95% CI)
Baseline JSN 1.07 (0.95 to 1.22)
Swollen joint count 1.09 (1.01 to 1.18)
RF−/ACPA− Ref
RF+/ACPA− 1.80 (0.29 to 11.25)
RF−/ACPA+ 3.14 (0.34 to 28.66)
RF+/ACPA+ 4.00 (0.88 to 18.08)
Time average ESR 1.04 (1.02 to 1.06)
Group 40<55
Baseline JSN 1.02 (0.95 to 1.10)
Baseline Erosions 1.04 (0.98 to 1.10)
Ritchie Articular Index 0.96 (0.89 to 1.03)
Swollen joint count 1.00 (0.95 to 1.10)
RF−/ACPA− Ref
RF+/ACPA− 2.67 (0.76 to 9.39)
RF−/ACPA+ 1.28 (0.37 to 4.43)
RF+/ACPA+ 2.65 (0.95 to 7.38)
Time average ESR 1.01 (0.99 to 1.04)
Group 55
Smoking at baseline 1.46 (0.81 to 2.63)
RF−/ACPA− Ref
RF+/ACPA− 1.33 (0.45 to 3.98)
RF−ACPA+ 2.31 (0.75 to 7.10)
RF+/ACPA+ 3.27 (1.25 to 8.53)
Time average ESR 1.02 (1.00 to 1.03)
Bold typeface represents risk factors that attained significance.
95% CI, 95% CI after Bonferroni correction; ACPA, anticitrullinated
protein antibodies; Erosions, erosion score (SHS); ESR, erythrocyte
sedimentation rate; JSN, joint space narrowing; RF, rheumatoid
factor; RR, relative risk; SHS, Sharp/van der Heijde score.
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multivariate Poisson regression, in group <40 baseline
SJC (1.09 (1.01–1.18)) and average ESR (1.04 (1.02–
1.06)) were independently associated with JSN progres-
sion. In group 40<55 none of the risk factors were sig-
niﬁcantly correlated, but the inﬂuence of the combined
presence of RF and ACPA showed a trend (4.00 (0.88–
18.10)). In group 55 the 10-year average ESR (1.02
(1.00–1.03)) and the combined presence of RF and
ACPA (3.27 (1.25–8.53)) were signiﬁcantly associated
with JSN progression. If only baseline variables were
incorporated in the multivariate model, similar results
were yielded; however, the inﬂuence of the combined
presence of RF and ACPA in group 40<55 attained sig-
niﬁcance (data not shown).
DISCUSSION
Radiographic damage progression, as potential cause of
permanent disability, is an important target for prevent-
ive therapy and one of the main determinants of suc-
cessful treatment in patients with RA. However, in some
patients with RA primary OA, represented by JSN may
contribute to radiographic joint damage progression.
Previous cross-sectional studies10–12 14 have shown that
older patients with RA had higher damage scores than
younger patients with RA at baseline, partly explained by
higher JSN.10 11 In addition, radiographic OA is more
often present in older patients and progression is more
frequent and more severe in older patients. Risk factors
for OA progression differ from risk factors for RA
progression.6–8
We hypothesised that older patients with RA also show
more JSN progression over time than younger patients,
because progression in JSN is caused by both RA and
OA, and that progression of JSN was associated with dif-
ferent risk factors in different age groups.
To investigate our hypothesis, we compared the sever-
ity of JSN between the age groups and tried to identify
age group-speciﬁc risk factors in a cohort of patients
with recent onset RA (1987 criteria), who were treated
to target DAS≤2.4 over the course of 10 years, with
three-monthly DAS calculation and treatment adjust-
ments, and radiographs of hands and feet taken at base-
line and yearly thereafter. JSN scores were derived from
the SHS.
As expected, we found that patients with RA of
55 years old showed JSN more often and more severe
JSN at baseline than younger patients. It was shown that
while damage to the proximal interphalangeal joints at
baseline increases with age, damage to the metacarpo-
phalangeal joints does not. Older patients had higher
ESR, higher SJC, higher DAS and a higher baseline
erosion score suggesting that in older patients there was
more rheumatoid inﬂammation. After 10 years, there
were no statistically signiﬁcant differences between the
age groups in the amount of JSN progression, but JSN
progression was more skewed to the right in the young-
est group, as reﬂected by a higher mean and higher SD
in that group. Risk factors for JSN progression were only
slightly different in the three age groups. In patients
55 years, the presence of RF and ACPA and a high
ESR as marker for systemic inﬂammation over time were
independent risk factors for JSN progression. Also in
patients <40 years, high inﬂammatory activity, repre-
sented by baseline SJC and ESR over time, was inde-
pendently associated with JSN progression, but the
presence of autoantibodies was not. In the >40 ≤55 years
age group there were no independent predictors for
JSN progression.
These results conﬁrm previous reports that JSN is
more prevalent and more severe in older patients with
RA than in younger patients at baseline. However, con-
trary to our hypothesis, we did not ﬁnd more JSN pro-
gression in older patients. In fact, the most severe JSN
progression was observed in (a subgroup of) patients
<40 years. Slow progression observed in (a subgroup of)
older patients may in part represent JSN due to primary
OA, which has been shown to be slowly progressive and
more prevalent in older patients.7 8 19
This hypothesis is supported by the fact that, although
ESR over time was higher in the oldest group than in
the other age groups, as is observed in healthy indivi-
duals,20 DAS over time was not, indicating that the SJCs
and Ritchie Articular Index results over time were low.
RA appears to have been well suppressed in the older
patients, which is also suggested by the ﬁnding that the
mean erosion progression score was lower than in the
other age groups. Primary OA is supposed to be relatively
rare in the ≤40 years age group, but over 10 years follow-up
may have progressively occurred, adding to the increased
JSN progression scores due to inﬂammation in those
patients. However, in the younger patients, erosion progres-
sion scores were also higher, suggesting that from baseline,
when they had a higher SJC, over 10 years follow-up, when
they had similar DAS but lower ESR, RA may have been
insufﬁciently suppressed. That initial combination therapy
in the older patients is not associated with less JSN progres-
sion may suggest that JSN progression in older patients is
caused by OA which is less susceptible to the treatment
with TNF inhibitors.21 However, in older patients, the com-
bined presence of RF and ACPA was associated with more
damage progression. In general, these antibodies have
been associated with a more destructive disease course in
RA. A previous analysis of the BeSt study22 showed that
presence of ACPA did not affect the suppression of inﬂam-
mation, but even in patients with similar low disease activity
was associated with more damage progression. Why this is
not found for younger patients in this study remains to be
investigated, but might be explained by the smaller sample
size in the age group <40.
Previous studies have looked at the possible contribu-
tion of primary OA to JSN scores in patients with
RA14 23 24 by multivariate linear analysis adjusted for
age. This statistical method assumes a linearity of the
relationship between age and outcome that may not
exist in the oldest patients11 and does not take into
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account the non-linear interaction between some risk
factors and age. By stratifying into different age groups,
we could assess non-linear relations between age and
risk factors. The downside of our method is a loss of
power and the loss of differentiation between ages that
belong in one age group. The age limits per group were
set arbitrarily, in part based on the median age in the
total group (55 years), the need for sufﬁcient numbers
of patients per group and the presumption that signiﬁ-
cant primary OA is unlikely in patients under 40 years
old. We were able to follow patients for 10 years, whereas
previous studies had shorter follow-up periods. During
these 10 years all patients received treatment targeted at
a DAS ≤2.4. This resulted, as previous analyses17 have
shown, in similarly well-controlled rheumatoid disease
activity in all patients in the four strategy arms from
1 year onwards.
It can be argued that to distinguish primary OA from
rheumatoid joint damage, one of the speciﬁc scoring
methods for OA should have been used.19 These however
may also include rheumatoid joint damage in the score,
and it remains unclear which is the best method to score
OA progression. Instead, we looked at JSN as part of the
SHS, precisely to highlight that a method to measure out-
comes of RA treatment can be susceptible to overesti-
mation of rheumatoid damage by including OA. Our
hypothesis that JSN in older patients is caused by RA and
OA was supported by increasing JSN at baseline in the
proximal interphalangeal joints but not in the metacarpo-
phalangeal joints. However, the potentially combined pres-
ence of rheumatoid damage and osteoarthritic features
suggest that risk factors identiﬁed in our analyses might
also be risk factors for both causes of JSN progression.
In conclusion, in different age groups of patients with
RA, JSN scores and progression of JSN may be inﬂuenced
by various factors, one of which may be primary OA in the
older age groups. This may affect how radiographic
scoring methods can be interpreted to represent treat-
ment effects of antirheumatic therapy in different age
groups. In all patients, inﬂammation should be optimally
suppressed to avoid the progression of joint damage which
may determine long-term functional ability. At baseline,
disease seems to be more severe in older persons, but after
10 years, radiographic outcomes do not differ between age
groups, implicating that progression in the younger
patients might not be optimally suppressed. Finally, a pos-
sible association between inﬂammation and progression of
OA should be further investigated by including speciﬁc
OA scoring methods and by evaluation in other cohorts, as
this knowledge may open a door to preventive treatment.
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